Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Shafrin

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Plos One|April 13, 2018
Estimated prevalence of undiagnosed atrial fibrillation in the United StatesMintu P Turakhia, Jason Shafrin, Katalin Bognar, et al.
Cancer Management and Research|December 15, 2017
The effect of medication nonadherence on progression-free survival among patients with renal cell carcinomaJason Shafrin, Jeffrey Sullivan, Jacquelyn W Chou, et al.
Journal of Managed Care & Specialty Pharmacy|October 27, 2016
Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with SchizophreniaJoanna P MacEwan, Felicia M Forma, Jason Shafrin, et al.
Current Medical Research and Opinion|August 27, 2025
Caregiver risk preferences for delaying loss of ambulation in Duchenne muscular dystrophy in the United StatesJason Shafrin, Nadine Zawadzki, Moises Marin, et al.
Health Affairs Scholar|March 24, 2025
Use of real-world evidence in the Medicare Drug Price Negotiation Program: A checklist for the Centers for Medicare and Medicaid Services and manufacturersSean R Tunis, Jason Shafrin, Kyi-Sin Than, et al.
Health Policy (Amsterdam, Netherlands)|May 8, 2018
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?Jason Shafrin, Michelle Skornicki, Michelle Brauer, et al.
BMJ Open|September 19, 2020
Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysisHoward Thom, Jeroen Jansen, Jason Shafrin, et al.
Journal of Market Access & Health Policy|February 23, 2026
Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic StrategiesKarim Ei-Kersh, Nadine Zawadzki, Catelyn Coyle, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2024
Quantifying the Value of Reduced Health Disparities: Low-Dose Computed Tomography Lung Cancer Screening of High-Risk Individuals Within the United StatesJason Shafrin, Jaehong Kim, Moises Marin, et al.
Journal of Medical Economics|July 19, 2021
Quantifying spillover benefits in value assessment: a case study of increased graft survival on the US kidney transplant waitlistSyvart Dennen, Oliver Díaz Espinosa, Kelly Birch, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Plos One|April 13, 2018
Estimated prevalence of undiagnosed atrial fibrillation in the United StatesMintu P Turakhia, Jason Shafrin, Katalin Bognar, et al.
Cancer Management and Research|December 15, 2017
The effect of medication nonadherence on progression-free survival among patients with renal cell carcinomaJason Shafrin, Jeffrey Sullivan, Jacquelyn W Chou, et al.
Journal of Managed Care & Specialty Pharmacy|October 27, 2016
Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with SchizophreniaJoanna P MacEwan, Felicia M Forma, Jason Shafrin, et al.
Current Medical Research and Opinion|August 27, 2025
Caregiver risk preferences for delaying loss of ambulation in Duchenne muscular dystrophy in the United StatesJason Shafrin, Nadine Zawadzki, Moises Marin, et al.
Health Affairs Scholar|March 24, 2025
Use of real-world evidence in the Medicare Drug Price Negotiation Program: A checklist for the Centers for Medicare and Medicaid Services and manufacturersSean R Tunis, Jason Shafrin, Kyi-Sin Than, et al.
Health Policy (Amsterdam, Netherlands)|May 8, 2018
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?Jason Shafrin, Michelle Skornicki, Michelle Brauer, et al.
BMJ Open|September 19, 2020
Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysisHoward Thom, Jeroen Jansen, Jason Shafrin, et al.
Journal of Market Access & Health Policy|February 23, 2026
Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic StrategiesKarim Ei-Kersh, Nadine Zawadzki, Catelyn Coyle, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2024
Quantifying the Value of Reduced Health Disparities: Low-Dose Computed Tomography Lung Cancer Screening of High-Risk Individuals Within the United StatesJason Shafrin, Jaehong Kim, Moises Marin, et al.
Journal of Medical Economics|July 19, 2021
Quantifying spillover benefits in value assessment: a case study of increased graft survival on the US kidney transplant waitlistSyvart Dennen, Oliver Díaz Espinosa, Kelly Birch, et al.
Pageof 9